PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1299208-6 1992 Ang II also facilitates the action of another trophic agent for cardiocytes, which is noradrenaline (NA). Norepinephrine 86-99 angiotensinogen Homo sapiens 0-6 1382168-4 1992 Recently, we have shown that stimulation of Ang II AT-1 receptors in the circumventricular organs causes a selective release of norepinephrine (NE) in the paraventricular nucleus (PVN) and in the supraoptic nucleus (SON). Norepinephrine 128-142 angiotensinogen Homo sapiens 44-50 1984867-1 1991 We tested the hypothesis that pressor infusions of angiotensin II (AII) could stimulate the sympathetic nervous system as reflected by norepinephrine (NE) spillover in humans. Norepinephrine 135-149 angiotensinogen Homo sapiens 51-65 1860093-1 1991 HYPOTHESIS: Reduction of plasma angiotensin II inhibits release of noradrenaline in response to a sympathetic nervous system stimulus. Norepinephrine 67-80 angiotensinogen Homo sapiens 32-46 1860093-14 1991 CONCLUSION: By blocking biosynthesis of angiotensin II, converting enzyme inhibition may attenuate baroreceptor-stimulated release of noradrenaline. Norepinephrine 134-147 angiotensinogen Homo sapiens 40-54 2063779-9 1991 In contrast, norepinephrine in ischemic patients increased significantly from 1.7 +/- 0.2 (control) to 2.6 +/- 0.3 (maximal pacing) and to 3.0 +/- 0.4 nmol/liter (1 minute after pacing), whereas angiotensin II levels increased from 6.2 +/- 1.4 (control) to 9.3 +/- 2.1 pmol/liter (1 minute after pacing, p less than 0.05). Norepinephrine 13-27 angiotensinogen Homo sapiens 195-209 1984867-1 1991 We tested the hypothesis that pressor infusions of angiotensin II (AII) could stimulate the sympathetic nervous system as reflected by norepinephrine (NE) spillover in humans. Norepinephrine 135-149 angiotensinogen Homo sapiens 67-70 1886454-1 1991 We examined the possible involvement of angiotensin II in the modulation of circulating norepinephrine produced by acute sodium restriction in essential hypertensive patients (n = 18). Norepinephrine 88-102 angiotensinogen Homo sapiens 40-54 1743243-0 1991 The effect of angiotensin II on haemodynamic and plasma noradrenaline responses to tyramine infusion in man. Norepinephrine 56-69 angiotensinogen Homo sapiens 14-28 2046466-0 1991 Effects of angiotensin II on pressor responses to norepinephrine in humans. Norepinephrine 50-64 angiotensinogen Homo sapiens 11-25 2046466-1 1991 In previous studies in the conscious rabbit and in isolated artery preparations, low doses of angiotensin II synergistically amplified the pressor effects of the sympathetic neurotransmitter, norepinephrine (NE). Norepinephrine 192-206 angiotensinogen Homo sapiens 94-108 1886454-3 1991 An intravenous infusion of sarcosine-1, isoleucine-8 angiotensin II produced a significant fall in mean arterial pressure (-6 +/- 2 mmHg, p less than 0.05) in patients on sodium restriction but not before sodium restriction, while the infusion of the antagonist produced a greater decrease (p less than 0.05) in plasma norepinephrine with sodium restriction (-158 +/- 23 pg/ml, p less than 0.05) when compared to that obtained before sodium restriction (-91 +/- 11 pg/ml, p less than 0.05). Norepinephrine 319-333 angiotensinogen Homo sapiens 53-67 1994180-1 1991 An attenuation of adrenergic activity during the inhibition of endogenous angiotensin II formation was evaluated by determining plasma norepinephrine concentration after a single oral administration of captopril compared to that after nifedipine in essential hypertension. Norepinephrine 135-149 angiotensinogen Homo sapiens 74-88 7649580-1 1995 The aim of this study was to investigate angiotensin II (Ang II) receptor-, bradykinin receptor-, and beta-adrenergic receptor-mediated modulation of norepinephrine release from human renal sympathetic nerves and to characterize the respective receptor subtypes involved. Norepinephrine 150-164 angiotensinogen Homo sapiens 41-55 2151360-0 1990 Atrial natriuretic peptide and angiotensin II interaction on noradrenaline uptake in the central nervous system. Norepinephrine 61-74 angiotensinogen Homo sapiens 31-45 2151360-1 1990 The effects of different concentrations of atrial natriuretic peptide and angiotensin II on [3H]-noradrenaline uptake in hypothalamus and medulla oblongata slices incubated in vitro were determined. Norepinephrine 97-110 angiotensinogen Homo sapiens 74-88 2151360-3 1990 The ineffective concentration of 1 nM atrial natriuretic peptide reversed the action of 1 microM of angiotensin II on [3H]-noradrenaline uptake, whereas ineffective concentrations of angiotensin II failed to modify atrial natriuretic peptide effects. Norepinephrine 123-136 angiotensinogen Homo sapiens 100-114 7649580-1 1995 The aim of this study was to investigate angiotensin II (Ang II) receptor-, bradykinin receptor-, and beta-adrenergic receptor-mediated modulation of norepinephrine release from human renal sympathetic nerves and to characterize the respective receptor subtypes involved. Norepinephrine 150-164 angiotensinogen Homo sapiens 57-63 35232218-6 2022 Net norepinephrine-induced vasoconstriction was exaggerated in adults with MDD (-0.16+-0.54 HA versus -0.75+-0.56 au MDD, P=0.014); however, there were no group differences in angiotensin II-induced vasoconstriction. Norepinephrine 4-18 angiotensinogen Homo sapiens 176-190 33031192-3 2021 The hemodynamic response to angiotensin II was estimated by recording the mean arterial pressure, norepinephrine equivalent dose (NED) and urine output. Norepinephrine 98-112 angiotensinogen Homo sapiens 28-42 35171852-9 2022 CONCLUSIONS: In cardiac surgery patients with hypotonia and postoperative high Delta-renin levels, AT-II was associated with reduced renin plasma levels for at 12 hours and significantly decreased norepinephrine use, while norepinephrine alone was associated with increased renin levels. Norepinephrine 197-211 angiotensinogen Homo sapiens 99-104 34614428-2 2021 Angiotensin II causes constriction of arterioles and venules, inhibits the reuptake of norepinephrine, stimulates the release of catecholamines, and hypertrophy of vascular smooth muscle cells. Norepinephrine 87-101 angiotensinogen Homo sapiens 0-14 2757896-12 1989 Angiotensin II when infused with placebo caused a 37% fall in absolute sodium excretion and a 32% fall when infused with noradrenaline (no significant difference between the 2 days). Norepinephrine 121-134 angiotensinogen Homo sapiens 0-14 3279724-10 1988 The changes in plasma noradrenaline as related to blood pressure, heart rate, plasma renin activity and angiotensin II during long-term felodipine treatment may reflect decreased cardiac and renal beta-adrenoceptor-mediated responses. Norepinephrine 22-35 angiotensinogen Homo sapiens 104-118 2690910-8 1989 In addition, converting enzyme inhibitors may directly (by a prejunctional effect) and indirectly (by curtailing the production of angiotensin II) reduce the release of noradrenaline in the blood vessel wall. Norepinephrine 169-182 angiotensinogen Homo sapiens 131-145 2848203-9 1988 Furthermore, the beta 2-adrenoceptor-induced facilitation of noradrenaline release may in part be mediated by local stimulation of angiotensin II synthesis, which may occur by increased formation or activation of renin and/or increased availability of angiotensinogen. Norepinephrine 61-74 angiotensinogen Homo sapiens 131-145 2852643-2 1988 A large body of in vitro and in vivo animal data indicate that angiotensin II regulates noradrenaline release and modifies sympathetic reflexes, although the physiological relevance of these to normal man remains unclear. Norepinephrine 88-101 angiotensinogen Homo sapiens 63-77 2852643-4 1988 The hypothesis was therefore examined that angiotensin II exerts a pre-junctional effect on noradrenaline release and sympathetic cardiovascular function, in the elderly and in patients with essential hypertension. Norepinephrine 92-105 angiotensinogen Homo sapiens 43-57 3440094-0 1987 The effect of angiotensin II on endogenous noradrenaline release in man. Norepinephrine 43-56 angiotensinogen Homo sapiens 14-28 3440094-2 1987 Considerable data from animal studies suggest that angiotensin II exerts a facilitatory effect on noradrenaline release. Norepinephrine 98-111 angiotensinogen Homo sapiens 51-65 3440094-3 1987 We sought evidence for such an effect in man by examining how a subpressor dose of angiotensin II (1.5 ng kg-1 min-1) influences the haemodynamic and plasma noradrenaline responses to physiological stimulation of the sympathetic nervous system. Norepinephrine 157-170 angiotensinogen Homo sapiens 83-97 3481814-2 1987 We sought evidence for a similar interaction in man, to determine whether this interaction is presynaptic, whereby angiotensin II (ANG II) facilitates noradrenaline (NA) release, or postsynaptic, whereby ANG II facilitates the effect of NA. Norepinephrine 151-164 angiotensinogen Homo sapiens 131-137 3453392-0 1987 Angiotensin II potentiates the vasoconstrictive effect of norepinephrine in normotensive and hypertensive man. Norepinephrine 58-72 angiotensinogen Homo sapiens 0-14 3453392-2 1987 Angiotensin II given in subpressor doses has been shown to enhance the vasoconstrictive effect of norepinephrine in several animal models. Norepinephrine 98-112 angiotensinogen Homo sapiens 0-14 3453392-3 1987 However, the effects of subpressor doses of angiotensin II on the vasoconstrictor effects of norepinephrine have not been reported in humans. Norepinephrine 93-107 angiotensinogen Homo sapiens 44-58 3453392-4 1987 We found that angiotensin II, given in subpressor doses, potentiates the vascular response of norepinephrine in normotensive and hypertensive male subjects. Norepinephrine 94-108 angiotensinogen Homo sapiens 14-28 3154309-3 1987 Since vascular resistance can be viewed as a net balance of offsetting vasoconstrictor and vasodilator neurohumoral forces, and since angiotensin II and norepinephrine can stimulate the synthesis of vasodilator prostaglandins that can in turn counteract peripheral vasoconstriction, we measured changes in vasoconstrictor (angiotensin II) and vasodilator (PGE2) hormones after giving different antihypertensive drugs. Norepinephrine 153-167 angiotensinogen Homo sapiens 323-337 3429867-1 1987 Much animal evidence exists to suggest that there is an interaction between noradrenaline (NA) and angiotensin II (AII). Norepinephrine 76-89 angiotensinogen Homo sapiens 99-113 3429867-1 1987 Much animal evidence exists to suggest that there is an interaction between noradrenaline (NA) and angiotensin II (AII). Norepinephrine 76-89 angiotensinogen Homo sapiens 115-118 3628271-0 1987 Angiotensin II induced amplification of the vasoconstrictor response to norepinephrine and clonidine. Norepinephrine 72-86 angiotensinogen Homo sapiens 0-14 3533124-1 1986 There is much animal data to suggest that angiotensin II has a regulatory role in noradrenaline release. Norepinephrine 82-95 angiotensinogen Homo sapiens 42-56 3021940-8 1986 Angiotensin II secreted from the vascular bed by the beta 2-adrenoceptor stimulation acts locally to facilitate norepinephrine release. Norepinephrine 112-126 angiotensinogen Homo sapiens 0-14 3534860-7 1986 The following sympathetic components may contribute to the effect of angiotensin II:ganglionic stimulation; enhanced release of noradrenaline (tyramine-like effect); inhibited noradrenaline re-uptake; facilitation of noradrenaline release via presynaptic AII-receptors; sensitization of postsynaptic alpha-adrenoceptors. Norepinephrine 128-141 angiotensinogen Homo sapiens 69-83 3534860-7 1986 The following sympathetic components may contribute to the effect of angiotensin II:ganglionic stimulation; enhanced release of noradrenaline (tyramine-like effect); inhibited noradrenaline re-uptake; facilitation of noradrenaline release via presynaptic AII-receptors; sensitization of postsynaptic alpha-adrenoceptors. Norepinephrine 176-189 angiotensinogen Homo sapiens 69-83 3534860-7 1986 The following sympathetic components may contribute to the effect of angiotensin II:ganglionic stimulation; enhanced release of noradrenaline (tyramine-like effect); inhibited noradrenaline re-uptake; facilitation of noradrenaline release via presynaptic AII-receptors; sensitization of postsynaptic alpha-adrenoceptors. Norepinephrine 176-189 angiotensinogen Homo sapiens 69-83 3893156-4 1985 The stimulation of jejunal absorption in response to ANG II is secondary to the release of norepinephrine (NE) from enteric sympathetic nerves. Norepinephrine 91-105 angiotensinogen Homo sapiens 53-59 2856713-9 1985 Angiotensin II contributes to the vasoconstrictive ability of the sympathetic nervous system, either through a direct vascular action or by enhancing the vascular responsiveness to noradrenaline stimulation. Norepinephrine 181-194 angiotensinogen Homo sapiens 0-14 6522858-0 1984 [Action mechanism of angiotensin II on norepinephrine release]. Norepinephrine 39-53 angiotensinogen Homo sapiens 21-35 2485262-0 1985 Reduced plasma noradrenaline during angiotensin II-induced acute hypertension in man. Norepinephrine 15-28 angiotensinogen Homo sapiens 36-50 6306616-5 1983 In contrast, simultaneous intracisternal administration of the angiotensin II antagonist, [Sar1, Val5, Ala8]-angiotensin II (saralasin), 1.1 nmol together with beta-endorphin, blunted the plasma epinephrine, norepinephrine and dopamine responses to beta-endorphin. Norepinephrine 208-222 angiotensinogen Homo sapiens 63-77 6705443-5 1984 beta-Blockade potentiated BP responses to norepinephrine and angiotensin II: Thirty-five percent less norepinephrine and 52% less angiotensin II were required to increase mean BP by 15 mm Hg. Norepinephrine 42-56 angiotensinogen Homo sapiens 130-144 6705443-5 1984 beta-Blockade potentiated BP responses to norepinephrine and angiotensin II: Thirty-five percent less norepinephrine and 52% less angiotensin II were required to increase mean BP by 15 mm Hg. Norepinephrine 102-116 angiotensinogen Homo sapiens 61-75 6306616-4 1983 Simultaneous intracisternal administration of angiotensin II 1.0 nmol together with synthetic human beta-endorphin 1.45 nmol potentiated the plasma epinephrine, norepinephrine and dopamine responses to intracisternal beta-endorphin. Norepinephrine 161-175 angiotensinogen Homo sapiens 46-60 6306616-5 1983 In contrast, simultaneous intracisternal administration of the angiotensin II antagonist, [Sar1, Val5, Ala8]-angiotensin II (saralasin), 1.1 nmol together with beta-endorphin, blunted the plasma epinephrine, norepinephrine and dopamine responses to beta-endorphin. Norepinephrine 208-222 angiotensinogen Homo sapiens 109-123 6126864-3 1982 Release of LHRH, somatostatin and vasopressin is affected by a variety of neurotransmitters or neuromodulators, such as norepinephrine, dopamine, epinephrine, histamine, cholinergic and opioid agonists, and peptides such as angiotensin II. Norepinephrine 120-134 angiotensinogen Homo sapiens 224-238 7040226-0 1982 Effect of inhibition of angiotensin II with captopril on renal overflow of norepinephrine. Norepinephrine 75-89 angiotensinogen Homo sapiens 24-38 7041592-13 1982 These results suggest that the attenuation by captopril of the pressor responses to norepinephrine and vasopressin might have been due to reduction of endogenous angiotensin II. Norepinephrine 84-98 angiotensinogen Homo sapiens 162-176 1216108-0 1975 Reflex stimulation of peripheral norepinephrine release: effect of nephrectomy and a physiological rate of angiotensin-II infusion. Norepinephrine 33-47 angiotensinogen Homo sapiens 107-121 7353356-8 1980 The increases in blood pressure in response to intravenous infusions of noradrenaline were significantly enhanced during vertebral artery infusions of acetylcholine and angiotensin II, but not of prostaglandin F2 alpha. Norepinephrine 72-85 angiotensinogen Homo sapiens 169-183 7353356-9 1980 The bradycardia during noradrenaline infusions was significantly enhanced by angiotensin II alone. Norepinephrine 23-36 angiotensinogen Homo sapiens 77-91 23967-4 1978 In addition, an increased responsiveness of isolated arterial strips to norepinephrine as well as other agonists appears to contribute to the adrenergic potentiating effect of angiotensin II as well as angiotensin III. Norepinephrine 72-86 angiotensinogen Homo sapiens 176-190 7001086-3 1980 Reduction of the urinary noradrenaline levels by the administration of angiotensin converting enzyme inhibitor (SQ-14225) suggested that the high urinary noradrenaline probably resulted from hyperreninemia which reflected high plasma levels of angiotensin II. Norepinephrine 25-38 angiotensinogen Homo sapiens 244-258 7001086-3 1980 Reduction of the urinary noradrenaline levels by the administration of angiotensin converting enzyme inhibitor (SQ-14225) suggested that the high urinary noradrenaline probably resulted from hyperreninemia which reflected high plasma levels of angiotensin II. Norepinephrine 154-167 angiotensinogen Homo sapiens 244-258 666671-1 1978 In acute experiments on the in utero foetal lamb, angiotensin II was a more potent pressor agent that either noradrenaline or adrenaline, and the response to angiotensin II was not consistently modified by the combined administration of alpha and beta-adrenergic blocking agents. Norepinephrine 109-122 angiotensinogen Homo sapiens 50-64 666671-6 1978 It is concluded that the foetus, like the adult animal, is more sensitive to angiotensin II than to catecholamines and that the biological activities of noradrenaline, angiotensin II, adrenaline and isoprenaline are reduced by perfusion through the foetal placenta. Norepinephrine 154-167 angiotensinogen Homo sapiens 78-92 1052611-0 1976 Immunization against angiotensin II and its relationship with the norepinephrine content of the hypothalamus and medulla oblongata. Norepinephrine 66-80 angiotensinogen Homo sapiens 21-35 32028998-10 2020 In such patients, a high ANG I/II ratio is associated with greater norepinephrine requirements and is an independent predictor of mortality, thus providing a biological rationale for interventions aimed at its correction. Norepinephrine 67-81 angiotensinogen Homo sapiens 25-30 4376675-0 1974 The involvement of calcium and angiotensin II in vascular reactivity to noradrenaline in renal/salt hypertension. Norepinephrine 72-85 angiotensinogen Homo sapiens 31-45 4306902-0 1969 Inhibition of norepinephrine uptake in hearts by angiotensin II and analogs. Norepinephrine 14-28 angiotensinogen Homo sapiens 49-63 14311457-0 1964 [EFFECT OF SYNTHETIC ANGIOTENSIN-II ON THE ARTERIAL PRESSURE OF DIFFERENT KINDS OF LABORATORY ANIMALS AND COMPARATIVE STUDY OF THIS ACTION WITH ADRENALINE AND NORADRENALINE]. Norepinephrine 159-172 angiotensinogen Homo sapiens 21-35 32931196-8 2020 Angiotensin II caused a significant increase in mean arterial pressure and a rapid reduction in catecholamine vasopressor doses from 0.75 to 0.31 mcg/kg/min norepinephrine equivalents. Norepinephrine 157-171 angiotensinogen Homo sapiens 0-14 4341975-0 1972 In vitro effects on cardiac norepinephrine of angiotensin II and of two indirectly acting sympathomimetic amines (amphetamine and tyramine). Norepinephrine 28-42 angiotensinogen Homo sapiens 46-60 4347475-0 1971 Selective release of newly synthesized cardiac norepinephrine induced by angiotensin II. Norepinephrine 47-61 angiotensinogen Homo sapiens 73-87 4321672-0 1970 [Action, in vitro and in vivo, of angiotensin II on cardiac uptake of noradrenaline]. Norepinephrine 70-83 angiotensinogen Homo sapiens 34-48 32984826-3 2020 Angiotensin II was initiated when the patient was requiring 2.2 microg/kg/min norepinephrine equivalents of vasopressor support, resulting in a prompt increase in the perfusion pressure. Norepinephrine 78-92 angiotensinogen Homo sapiens 0-14 29504268-4 2018 Second, the high Ang II dose exerted a novel differential effect on arterial contractile responsiveness to the sympathetic neurotransmitter, norepinephrine, depending on the level of sympathetic innervation. Norepinephrine 141-155 angiotensinogen Homo sapiens 17-23 31161442-4 2019 RESULTS: The subgroup of patients whose angiotensin II dose was down-titrated from 20 ng kg-1 min-1 at treatment initiation to <= 5 ng kg-1 min-1 at 30 min (79/163) had significantly lower endogenous serum angiotensin II levels and norepinephrine-equivalent doses and significantly higher MAP versus the > 5 ng kg-1 min-1 subgroup (84/163). Norepinephrine 235-249 angiotensinogen Homo sapiens 40-54 30341700-6 2019 Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. Norepinephrine 196-210 angiotensinogen Homo sapiens 14-28 30341700-9 2019 In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Norepinephrine 67-81 angiotensinogen Homo sapiens 38-52 30341700-9 2019 In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Norepinephrine 117-131 angiotensinogen Homo sapiens 38-52 31061349-3 2019 In addition, indirect vascular contractions induced by noradrenaline (NA), the release of which is mediated through Ang II receptor type 1 (AT1) existing at the sympathetic nerve terminals (SNTs), also contribute to the vasopressor effects of Ang II. Norepinephrine 55-68 angiotensinogen Homo sapiens 116-122 29868972-9 2018 Vasopressin and possibly angiotensin II may be useful owing to their norepinephrine-sparing effects. Norepinephrine 69-83 angiotensinogen Homo sapiens 25-39 16507050-6 2006 The actions of several factors beside noradrenaline (e.g. endothelin-1, angiotensin II), possibly involved in the increased smooth muscle activity found in both LUTS/BPH and sexual dysfunction, are dependent on Rho-kinase activity. Norepinephrine 38-51 angiotensinogen Homo sapiens 72-86 28215131-5 2017 Calculation of a norepinephrine-equivalent vasopressor dose is critical to determining patient eligibility, as ANGII will supplement ongoing vasopressor therapy. Norepinephrine 17-31 angiotensinogen Homo sapiens 111-116 21145919-10 2011 The distinct colocalization of neuronal Ang II with DbetaH in the heart may indicate that Ang II participates together with norepinephrine in the regulation of cardiac functions: produced as a cardiac neurotransmitter Ang II may have inotropic, chronotropic or dromotropic effects in atria and ventricles and contributes to blood pressure regulation. Norepinephrine 124-138 angiotensinogen Homo sapiens 40-46 19223317-7 2009 Cardiac norepinephrine increased seven-fold, possibly due to the rise in angiotensin II. Norepinephrine 8-22 angiotensinogen Homo sapiens 73-87 18093411-3 2007 Angiotensin II also stimulates noradrenaline release modulated by presynaptic receptors on sympathetic nerves. Norepinephrine 31-44 angiotensinogen Homo sapiens 0-14 28641333-4 2017 Recent findings implicate brain RAS, especially Angiotensin II (Ang II), in neural pathophysiology of mental disorders through neuroendocrine modulation and effects on neurotransmitter release, mostly noradrenaline, acetylcholine and dopamine. Norepinephrine 201-214 angiotensinogen Homo sapiens 64-70 27207905-11 2016 Angiotensin II is known to facilitate the effects of norepinephrine, which contributes to methamphetamine"s subjective effects. Norepinephrine 53-67 angiotensinogen Homo sapiens 0-14 23225134-8 2014 In peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity seen in chronic heart failure. Norepinephrine 52-66 angiotensinogen Homo sapiens 23-37 23225134-8 2014 In peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity seen in chronic heart failure. Norepinephrine 102-116 angiotensinogen Homo sapiens 23-37 24583830-6 2014 Our results suggest that cold air exposure increases blood pressure in cardiovascular disease patients and healthy subjects via the sympathetic nervous system (SNS) that is activated first and which augments ANG-II levels accelerating the release of the norepinephrine and stimulates the renin-angiotensin system (RAS). Norepinephrine 254-268 angiotensinogen Homo sapiens 208-214 24295263-6 2013 RESULTS: Endothelin 1, oxytocin, prostaglandin F2alpha, norepinephrine, and phenylephrine induced dose-dependent contraction of the isolated urethral tissue, whereas acetylcholine, carbachol, and angiotensin II had no or only minor contractile effects. Norepinephrine 56-70 angiotensinogen Homo sapiens 196-210 24194850-0 2013 Ang II enhances noradrenaline release from sympathetic nerve endings thus contributing to the up-regulation of metalloprotease-2 in aortic dissection patients" aorta wall. Norepinephrine 16-29 angiotensinogen Homo sapiens 0-6 24194850-1 2013 OBJECT: To test the hypothesis that angiotensin II (Ang II) could enhance noradrenaline (NA) release from sympathetic nerve endings of the aorta thus contributing to the up-regulation of matrix metalloproteinase 2 (MMP-2) during the formation of aortic dissection (AD). Norepinephrine 74-87 angiotensinogen Homo sapiens 36-50 24194850-1 2013 OBJECT: To test the hypothesis that angiotensin II (Ang II) could enhance noradrenaline (NA) release from sympathetic nerve endings of the aorta thus contributing to the up-regulation of matrix metalloproteinase 2 (MMP-2) during the formation of aortic dissection (AD). Norepinephrine 74-87 angiotensinogen Homo sapiens 52-58 19829312-3 2009 Their study demonstrates a calcium-independent enhanced contractile response to angiotensin II following norepinephrine administration. Norepinephrine 105-119 angiotensinogen Homo sapiens 80-94 16513451-3 2006 We studied the influence of this polymorphism on the responses to angiotensin II antagonism in the presence of ET-1, norepinephrine, and angiotensin II. Norepinephrine 117-131 angiotensinogen Homo sapiens 66-80 15753325-8 2005 Vascular maladaptation with increased vasomotor tone, endothelial dysfunction, and increased sensitivity to angiotensin II and norepinephrine in manifest preeclampsia may be explained on the basis of angiotensin II-mediated mechanisms. Norepinephrine 127-141 angiotensinogen Homo sapiens 200-214 16116043-2 2005 We have previously shown that infusion of Ang II in the lateral cerebral ventricle raises blood pressure (BP), renal sympathetic nervous system activity (RSNA), and norepinephrine (NE) secretion from the posterior hypothalamic nuclei (PH), and reduces the abundance of interleukin-1beta (IL-1beta) and neuronal NO synthase (nNOS) mRNA in the PH. Norepinephrine 165-179 angiotensinogen Homo sapiens 42-48 15953595-1 2005 Numerous studies have shown that angiotensin II causes vasoconstriction both by a direct action on smooth muscle cells (postjunctional effect) and indirectly through the facilitation of noradrenaline release from postganglionic sympathetic neurons (prejunctional effect). Norepinephrine 186-199 angiotensinogen Homo sapiens 33-47 11602816-7 2001 Attenuation of norepinephrine release during exercise by valsartan suggests that angiotensin II facilitates the release of norepinephrine from sympathetic postganglionic neurons. Norepinephrine 15-29 angiotensinogen Homo sapiens 81-95 15361762-9 2004 CONCLUSIONS: These data suggest that functional vasoconstrictive endothelin-B receptors on vascular smooth muscle cells may contribute to the potentiating effects of high local concentrations of endothelin-1 on the vasoconstriction to noradrenaline and angiotensin II in human microcirculation. Norepinephrine 235-248 angiotensinogen Homo sapiens 253-267 12767723-1 2003 In addition to their physiological roles in the cardiovascular system (CVS), G-protein-coupled receptor (GPCR) agonists such as noradrenaline, endothelin-1 and angiotensin II (Ang II) are known to be involved in the development of cardiac hypertrophy. Norepinephrine 128-141 angiotensinogen Homo sapiens 176-182 12609747-0 2003 Angiotensin II-induced release of oxytocin: interaction with norepinephrine and role in lactation. Norepinephrine 61-75 angiotensinogen Homo sapiens 0-14 12609747-8 2003 These data demonstrate that Ang II evoked OT release is mediated through activation of both AT1 and AT2 receptors and suggest that a component of Ang II-induced OT stimulation is due to norepinephrine release. Norepinephrine 186-200 angiotensinogen Homo sapiens 146-152 15383007-1 2005 ANG II (angiotensin II) facilitates catecholamine release from the adrenal medulla and neuronal NE (noradrenaline) release. Norepinephrine 100-113 angiotensinogen Homo sapiens 8-22 12130713-1 2002 We recently reported that in the ischemic human heart, locally formed angiotensin II activates angiotensin II type 1 (AT(1)) receptors on sympathetic nerve terminals, promoting reversal of the norepinephrine transporter in an outward direction (i.e., carrier-mediated norepinephrine release). Norepinephrine 193-207 angiotensinogen Homo sapiens 70-84 12130713-8 2002 Our findings uncover a novel autocrine/paracrine mechanism whereby angiotensin II, formed at adrenergic nerve endings in myocardial ischemia, elicits carrier-mediated norepinephrine release by activating adjacent AT(1) receptors. Norepinephrine 167-181 angiotensinogen Homo sapiens 67-81 11602816-7 2001 Attenuation of norepinephrine release during exercise by valsartan suggests that angiotensin II facilitates the release of norepinephrine from sympathetic postganglionic neurons. Norepinephrine 123-137 angiotensinogen Homo sapiens 81-95 11602816-8 2001 Angiotensin II, therefore, contributes to the pressor response to exercise by inducing peripheral vasoconstriction and facilitation of norepinephrine release from postganglionic sympathetic nerve endings that are unrelated to central activation of the autonomic nervous system. Norepinephrine 135-149 angiotensinogen Homo sapiens 0-14 11108138-3 2000 The addition of norepinephrine (NE), isoproterenol (a beta1/beta2-adrenergic receptor (AR) agonist) and iodoclonidine (an alpha2-AR agonist) stimulated the expression of the ANG-GH fusion gene in a dose-dependent manner, whereas the addition of epinephrine and phenylephrine (alpha1-AR agonist) had no effect. Norepinephrine 16-30 angiotensinogen Homo sapiens 174-177 11164180-9 2001 RESULTS: In vitro, BK, forskolin, and sodium nitroprusside elicited dose-dependent relaxation of norepinephrine-induced tension of isolated HCC, and AN II evoked dose-dependent contraction of the HCC strips. Norepinephrine 97-111 angiotensinogen Homo sapiens 149-154 10871319-1 2000 Angiotensin II (Ang II) promotes norepinephrine (NE) release from cardiac sympathetic nerve endings. Norepinephrine 33-47 angiotensinogen Homo sapiens 0-22 10691803-5 2000 The antinatriuretic effects of noradrenaline, acting on alpha-adrenoceptors and angiotensin II are opposed by dopamine as well as by atrial natriuretic peptide (ANP). Norepinephrine 31-44 angiotensinogen Homo sapiens 80-94 10702208-4 2000 RESULTS: In all groups, ANG II and norepinephrine caused dose-dependent reductions in FBF (P < 0.001); responses to norepinephrine were similar across the 3 groups but those to ANG II were less in both cirrhotic groups than in controls (P < 0.01). Norepinephrine 35-49 angiotensinogen Homo sapiens 180-186 9715790-8 1998 Intranasal ANG II also counteracted the decrease in norepinephrine levels observed after intravenous administration of ANG II. Norepinephrine 52-66 angiotensinogen Homo sapiens 11-17 10610744-10 2000 04) and norepinephrine (P=0.04) were univariately associated with increased angiotensin II. Norepinephrine 8-22 angiotensinogen Homo sapiens 76-90 10610744-11 2000 Multivariate regression analysis identified the plasma renin activity (0.0004), norepinephrine (0.02) and interleukin-6 (0.03) as independent predictors of plasma angiotensin II. Norepinephrine 80-94 angiotensinogen Homo sapiens 163-177 10361980-1 1999 Previous studies have shown that while vasopressin and angiotensin II are markedly more effective than norepinephrine and prostaglandin F2alpha in eliciting an acute elevation of inositol 1,4,5-trisphosphate (IP3), norepinephrine and prostaglandin F2alpha produce larger enhancement of DNA synthesis. Norepinephrine 215-229 angiotensinogen Homo sapiens 55-69 10361980-4 1999 which remain elevated for at least 60 min., while norepinephrine and prostaglandin F2alpha elevate IP3 levels slightly and transiently For vasopressin the dose-effect curves for IP3 accumulation and stimulation of DNA synthesis were closely parallel, while this was not the case for angiotensin II, norepinephrine, or prostaglandin F2alpha. Norepinephrine 50-64 angiotensinogen Homo sapiens 283-297 10478564-7 1999 In conclusion, it can be assumed that the powerful vasoconstrictions induced by 8-iso-prostaglandin E2 and 8-iso-prostaglandin F2alpha and their potentiating effects on vasoconstrictions induced by noradrenaline or angiotensin II might be of pathophysiological relevance in cardiovascular diseases. Norepinephrine 198-211 angiotensinogen Homo sapiens 215-229 9715790-8 1998 Intranasal ANG II also counteracted the decrease in norepinephrine levels observed after intravenous administration of ANG II. Norepinephrine 52-66 angiotensinogen Homo sapiens 119-125 9454842-1 1998 Chronic stimulation of brain neurons by angiotensin II (Ang II) results in a increase in norepinephrine (NE) uptake. Norepinephrine 89-103 angiotensinogen Homo sapiens 40-54 9683925-6 1998 Noradrenaline, angiotensin II and L-NG-monomethyl arginine caused significant vasoconstriction (p < 0.001) in both patients and controls although angiotensin II caused significantly less vasoconstriction in patients (p = 0.01). Norepinephrine 0-13 angiotensinogen Homo sapiens 149-163 9454842-1 1998 Chronic stimulation of brain neurons by angiotensin II (Ang II) results in a increase in norepinephrine (NE) uptake. Norepinephrine 89-103 angiotensinogen Homo sapiens 56-62 9422390-2 1998 Raf-1-dependent activation of mitogen-activated protein kinase (MAPK) is the key in the chronic norepinephrine neuromodulatory actions of Ang II and is associated with the translocation of MAPK into the nucleus. Norepinephrine 96-110 angiotensinogen Homo sapiens 138-144 8681492-1 1996 BACKGROUND: One suggested mechanism for the reduction in mortality rates resulting from the use of angiotensin converting enzyme inhibitors in congestive heart failure is the inhibition of the angiotensin II-mediated norepinephrine release. Norepinephrine 217-231 angiotensinogen Homo sapiens 193-207 9135928-6 1997 Plasma norepinephrine levels were significantly higher on glibenclamide (6.41 +/- 1.77 vs. 4.26 +/- 1.54 mmol/l, P < 0.01), and systolic BP responses to intravenous norepinephrine and angiotensin II were significantly higher on glibenclamide than on metformin (P < 0.02 and P < 0.05, respectively). Norepinephrine 7-21 angiotensinogen Homo sapiens 187-201 9381945-2 1997 It is still under debate whether angiotensin II facilitates noradrenaline release in the heart. Norepinephrine 60-73 angiotensinogen Homo sapiens 33-47 8988485-9 1996 Fenoterol (1-1000 nM), a beta 2-adrenoceptor agonist, and angiotensin II (1-1000 nM) significantly increased noradrenaline release in a concentration-dependent manner. Norepinephrine 109-122 angiotensinogen Homo sapiens 25-72 8842454-17 1996 Angiotensin II (0.1 mumol l-1 enhanced noradrenaline release resulting in a S2/S1 ratio of 1.44 (1.34-1.54), while the angiotensin II antagonist, losartan (1 mumol l-1) had no effect on noradrenaline release during normoxia. Norepinephrine 39-52 angiotensinogen Homo sapiens 0-14 8842454-17 1996 Angiotensin II (0.1 mumol l-1 enhanced noradrenaline release resulting in a S2/S1 ratio of 1.44 (1.34-1.54), while the angiotensin II antagonist, losartan (1 mumol l-1) had no effect on noradrenaline release during normoxia. Norepinephrine 186-199 angiotensinogen Homo sapiens 0-14 8842454-20 1996 In conclusion, human cardiac tissue possesses presynaptic inhibitory alpha 2-adrenoceptors and adenosine receptors, as well as facilitatory beta 2-adrenoceptors and angiotensin II receptors regulating noradrenaline release under normoxic conditions. Norepinephrine 201-214 angiotensinogen Homo sapiens 165-179 7503249-1 1995 Acute elevations in circulating angiotensin II (ANG II) are known to increase circulating norepinephrine (NE) levels. Norepinephrine 90-104 angiotensinogen Homo sapiens 32-46 7503249-1 1995 Acute elevations in circulating angiotensin II (ANG II) are known to increase circulating norepinephrine (NE) levels. Norepinephrine 90-104 angiotensinogen Homo sapiens 48-54 7989494-4 1994 Angiotensin-II increased the release of norepinephrine and neuropeptide-Y by the pheochromocytes. Norepinephrine 40-54 angiotensinogen Homo sapiens 0-14 8984125-1 1995 OBJECTIVE: The existence of presynaptic angiotensin II receptors, modulating the release of the sympathetic neurotransmitter norepinephrine, was examined in the perfused human forearm model. Norepinephrine 125-139 angiotensinogen Homo sapiens 40-54 8984125-5 1995 In contrast, the spillover of norepinephrine even decreased during angiotensin II administration, both before and during intravenous sodium nitroprusside administration, probably because of angiotensin II-induced forearm vasoconstriction. Norepinephrine 30-44 angiotensinogen Homo sapiens 67-81 8984125-5 1995 In contrast, the spillover of norepinephrine even decreased during angiotensin II administration, both before and during intravenous sodium nitroprusside administration, probably because of angiotensin II-induced forearm vasoconstriction. Norepinephrine 30-44 angiotensinogen Homo sapiens 190-204 8984125-6 1995 Similar vasoconstrictor doses of angiotensin II and methoxamine produced similar changes in spillover and total plasma appearance rate of norepinephrine. Norepinephrine 138-152 angiotensinogen Homo sapiens 33-47 8584237-0 1995 The effect of the angiotensin II (AT1A) receptor stably transfected into human neuroblastoma SH-SY5Y cells on noradrenaline release and changes in intracellular calcium. Norepinephrine 110-123 angiotensinogen Homo sapiens 18-32 7582398-1 1995 Increasing animal evidence support an important facilitatory interaction between angiotensin II and norepinephrine within the kidney. Norepinephrine 100-114 angiotensinogen Homo sapiens 81-95 7798510-9 1995 Norepinephrine spillover declined during vehicle infusions (612 +/- 367 to 418 +/- 196 ng/min, p < 0.05) but not during angiotensin II infusions despite a greater increase in mean arterial pressure when the subpressor angiotensin II was combined with head-down tilt and phenylephrine (6.0 +/- 7.0 mm Hg during vehicle; 14 +/- 9.4 mm Hg during angiotensin II, p < 0.01). Norepinephrine 0-14 angiotensinogen Homo sapiens 221-235 7798510-9 1995 Norepinephrine spillover declined during vehicle infusions (612 +/- 367 to 418 +/- 196 ng/min, p < 0.05) but not during angiotensin II infusions despite a greater increase in mean arterial pressure when the subpressor angiotensin II was combined with head-down tilt and phenylephrine (6.0 +/- 7.0 mm Hg during vehicle; 14 +/- 9.4 mm Hg during angiotensin II, p < 0.01). Norepinephrine 0-14 angiotensinogen Homo sapiens 221-235 7989494-0 1994 Angiotensin-II mediates norepinephrine and neuropeptide-Y secretion in a human pheochromocytoma. Norepinephrine 24-38 angiotensinogen Homo sapiens 0-14 7611494-3 1995 Des-Asp1-angiotensin I, angiotensin I, II, and III produced similar increases in perfusion pressure and were approximately 300-fold more potent than (p-amino-Phe6)-angiotensin II, 100-fold more potent than angiotensin IV, 30-fold more potent than norepinephrine, and 10-fold more potent than U-46619. Norepinephrine 247-261 angiotensinogen Homo sapiens 9-22 7611494-3 1995 Des-Asp1-angiotensin I, angiotensin I, II, and III produced similar increases in perfusion pressure and were approximately 300-fold more potent than (p-amino-Phe6)-angiotensin II, 100-fold more potent than angiotensin IV, 30-fold more potent than norepinephrine, and 10-fold more potent than U-46619. Norepinephrine 247-261 angiotensinogen Homo sapiens 24-37 7721403-1 1995 Angiotensin II (Ang II) potentiates sympathetic neurotransmission by presynaptic facilitation of norepinephrine release. Norepinephrine 97-111 angiotensinogen Homo sapiens 0-22 7652508-4 1995 In animals pretreated with both estradiol benzoate and progesterone, exogenous A II stimulated the release of LH; (2) Brain endogenous A II may be involved in the preovulatory release of LH on proestrus; (3) A II affects LH secretion via LH-RH and norepinephrine in the brain. Norepinephrine 248-262 angiotensinogen Homo sapiens 79-83 7652508-4 1995 In animals pretreated with both estradiol benzoate and progesterone, exogenous A II stimulated the release of LH; (2) Brain endogenous A II may be involved in the preovulatory release of LH on proestrus; (3) A II affects LH secretion via LH-RH and norepinephrine in the brain. Norepinephrine 248-262 angiotensinogen Homo sapiens 135-139 7652508-4 1995 In animals pretreated with both estradiol benzoate and progesterone, exogenous A II stimulated the release of LH; (2) Brain endogenous A II may be involved in the preovulatory release of LH on proestrus; (3) A II affects LH secretion via LH-RH and norepinephrine in the brain. Norepinephrine 248-262 angiotensinogen Homo sapiens 135-139 7957611-3 1994 CGRP (10(-9) to 10(-7) M) and angiotensin II (10(-9) to 10(-5) M) caused concentration-dependent increases in force of contraction in atrial trabeculae (up to 36 +/- 8% and 42 +/- 8% of the response to 10(-5) M noradrenaline, respectively). Norepinephrine 211-224 angiotensinogen Homo sapiens 30-44 7894215-8 1994 In analogy to the results of experimental studies showing that angiotensin II and noradrenaline act as growth factors on cardiac and vascular cells, cardiovascular remodeling present in our patient with Bartter"s syndrome may be explained by increased activity of angiotensin II and/or noradrenaline. Norepinephrine 82-95 angiotensinogen Homo sapiens 264-278 7894215-8 1994 In analogy to the results of experimental studies showing that angiotensin II and noradrenaline act as growth factors on cardiac and vascular cells, cardiovascular remodeling present in our patient with Bartter"s syndrome may be explained by increased activity of angiotensin II and/or noradrenaline. Norepinephrine 286-299 angiotensinogen Homo sapiens 63-77 7954098-1 1994 In heart failure, both the sympathetic nervous system and the renin angiotensin system play important pathophysiological roles, and the two systems may interact with each other, e.g., angiotensin II facilitating noradrenaline release. Norepinephrine 212-225 angiotensinogen Homo sapiens 184-198 8024910-7 1994 The results support the concept that angiotensin II facilitates release of noradrenaline from sympathetic nerves and that ACE inhibition inhibits this release. Norepinephrine 75-88 angiotensinogen Homo sapiens 37-51 1337912-7 1992 Locally generated angiotensin II increased sympathetic vasoconstriction through the presynaptic release of noradrenaline and this effect was mediated by beta-adrenoceptor stimulation. Norepinephrine 107-120 angiotensinogen Homo sapiens 18-32 8025910-0 1994 Effect of angiotensin II on noradrenaline release in the human forearm. Norepinephrine 28-41 angiotensinogen Homo sapiens 10-24 8025910-1 1994 OBJECTIVE: The aim was to test the hypothesis that in normal humans angiotensin II would stimulate local release of noradrenaline under basal conditions or during a sympathetic stimulus provided by lower body negative pressure (LBNP). Norepinephrine 116-129 angiotensinogen Homo sapiens 68-82 8477561-3 1993 Angiotensin II increased significantly in response to infused norepinephrine during placebo administration (p < 0.001) but not during captopril administration (p = 0.15). Norepinephrine 62-76 angiotensinogen Homo sapiens 0-14 7519697-6 1994 In line with animal studies, vascular angiotensin II increases the vasoconstriction induced by the stimulation of the sympathetic nervous system through the potentiation of noradrenaline release at a presynaptic level, and this effect seems to be mediated by beta-adrenoceptor activation. Norepinephrine 173-186 angiotensinogen Homo sapiens 38-52 8293770-2 1993 Since all three peptides are able to modulate catecholamine release, a change in noradrenaline and adrenaline release should be expected when angiotensin I converting enzyme (kininase II) is inhibited. Norepinephrine 81-94 angiotensinogen Homo sapiens 142-155 8384645-2 1993 BACKGROUND: Angiotensin II has been shown experimentally to stimulate norepinephrine release. Norepinephrine 70-84 angiotensinogen Homo sapiens 12-26 8384645-12 1993 During head-down tilt, plasma norepinephrine decreased with both angiotensin II and the vehicle control. Norepinephrine 30-44 angiotensinogen Homo sapiens 65-79 1524760-9 1992 Thus, when the generation of angiotensin II was blocked by captopril the insulin-induced rise in epinephrine and norepinephrine was blunted. Norepinephrine 113-127 angiotensinogen Homo sapiens 29-43